01 August 2019
Visiongain has launched a new pharma report Global Rare Disease Drugs Market Report: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies.
The global rare disease drugs market is one that is driven by innovation which is vital for maintaining the rich pipeline of rare diseases drugs seen in the market today. There is an increasing focus to identify and treat rare diseases that currently are undertreated which creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market.
The lead analyst of the report commented "It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge. As a result, rare diseases lack published data on long-term outcomes of treatment and are often characterized incompletely. This requires exploring international and regional research partnerships, collaborating with doctors working on any rare disease, and with patient groups and families dealing with the consequences of these disorders."
Leading companies featured in the report AbbVie, Bristol-Myers Squibb (BMS), Celgene, Merck & Co., Inc., Novartis, Pfizer, Roche, Sanofi, Takeda, Teva and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Rising preference for personalised medicine in developed as well as developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase NGS market concentration over the forecast period.
04 June 2021
The rising frequency of bacterial and viral diseases coupled with increased focus on immunisation programmes are two main reasons that are expected to boost the global anti-infective vaccines market’s growth in the coming years.
04 June 2021
Rising incidences of infectious diseases is one of the prime factors driving the growth of the global anti-infective agents market globally.
27 May 2021
Healthcare has never been more personalized and affordable to anyone. Digital consulting applications use artificial intelligence to provide medical advice based on customized medical history record reviews and general medical information derived from big data inferences.